LEVO-T Drug Patent Profile

When do Levo-t patents expire, and what generic alternatives are available?

Levo-t is a drug marketed by Cediprof Inc and is included in one NDA.

The generic ingredient in LEVO-T is levothyroxine sodium. There are ten drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Levo-t

A generic version of LEVO-T was approved as levothyroxine sodium by MYLAN on June 5^th, 2002.

Summary for LEVO-T

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	14
Raw Ingredient (Bulk) Api Vendors:	63
Patent Applications:	3,045
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for LEVO-T
What excipients (inactive ingredients) are in LEVO-T?	LEVO-T excipients list
DailyMed Link:	LEVO-T at DailyMed

See drug prices for LEVO-T

Pharmacology for LEVO-T

Drug Class

l-Thyroxine

Anatomical Therapeutic Chemical (ATC) Classes for LEVO-T

H03AA	Thyroid hormones
H03A	THYROID PREPARATIONS
H03	THYROID THERAPY
H	Systemic hormonal preparations, excluding sex hormones and insulins

US Patents and Regulatory Information for LEVO-T

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-001	Mar 1, 2002	AB1,AB2,AB3	RX	No	No
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-007	Mar 1, 2002	AB1,AB2,AB3	RX	No	No
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-004	Mar 1, 2002	AB1,AB2,AB3	RX	No	No
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-011	Mar 1, 2002	AB1,AB2,AB3	RX	No	No
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-012	Dec 8, 2003	AB1,AB2,AB3	RX	No	No
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-002	Mar 1, 2002	AB1,AB2,AB3	RX	No	No
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-003	Mar 1, 2002	AB1,AB2,AB3	RX	No	No

Expired US Patents for LEVO-T

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-007	Mar 1, 2002
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-003	Mar 1, 2002
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-001	Mar 1, 2002
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-006	Mar 1, 2002
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-005	Mar 1, 2002
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-011	Mar 1, 2002
Cediprof Inc	LEVO-T	levothyroxine sodium	TABLET;ORAL	021342-004	Mar 1, 2002

International Patents for LEVO-T

See the table below for patents covering LEVO-T around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2003528931
Australia	5295301
World Intellectual Property Organization (WIPO)	0174448
Israel	152024	PHARMACEUTICAL COMPOSITIONS CONTAINING THYROID HORMONE AND PROCESSES FOR THE MANUFACTURE THEREOF
Canada	2404369
Brazil	0109736
Australia	2001252953